Enter your terms above and click the 'Search' button.

Showing articles 0 to 13 of 13 Filter Applied: alemtuzumab (Click to remove) Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis Neurol 102:e208006, Ng, HS.,et al, 2024 Simultaneous CMV and Listeria Infection Following Alemtuzumab Treatment for Multiple Sclerosis Neurol 92:296-298, Pappolla, A.,et al, 2019 Acute acalculous cholecystitis Neurol 90:e1548-e1552, Croteau, D.,et al, 2018 Myasthenia Gravis Following Alemtuzumab Therapy for Multiple Sclerosis Neurol 91:622-624, Midaglia, L.,et al, 2018 Alemtuzumab CARE-MS I 5-year follow-up Neurol 89:1107-1116, Havrdova, E.,et al, 2017 Alemtuzumab CARE-MS II 5-year follow-up Neurol 89:1117-1126, Coles, A.J.,et al, 2017 Fulminant Central Nervous System Nocardiosis in a Patient Treated with Alemtuzumab for Relapsing-Remitting Multiple Sclerosis JAMA Neurol 73:757-759, Penkert, H.,et al, 2016 Superior MRI Outcomes with Alemtuzumab Compared with Subcutaneous Interferon �-1a in MS Neurol 87:1464-1472, Arnold, D.L.,et al, 2016 Acute Cholecystitis During Treatment with Alemtuzumab in 3 Patients with RRMS Neurol 87:2380-2381, Pfeuffer, S.,et al, 2016 Newer Agents in the Treatment of Multiple Sclerosis Neurologist 19:104-117, Pawate, S. & Bagnato F., 2015 Monoclonal Antibody Therapies and Neurologic Disorders Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008 Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008 Emerging Monoclonal Antibody Therapies for Multiple Sclerosis Neurologist 12:171-178, Cree,B., 2006 Showing articles 0 to 13 of 13